Literature DB >> 6160026

Synthesis of methotrexate polyglutamates by bone marrow cells from patients with leukemia and lymphoma.

A Witte, V M Whitehead, D S Rosenblatt, M J Vuchich.   

Abstract

Bone marrow cells from children with lymphoblastic leukemia, myeloblastic leukemia and non-Hodgkin's lymphoma were incubated with tritium-labelled methotrexate in short-term cultures. Cells obtained both during disease activity as well as during remission synthesized large quantities of methotrexate polyglutamates. Synthesis was time- and dose-dependent and occurred with concentrations of methotrexate regularly achieved during conventional treatment with this drug.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6160026

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN： 0379-8305


  6 in total

1.  Pharmacokinetics of methotrexate in erythrocytes in psoriasis.

Authors:  J Hendel; A Nyfors
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Methotrexate in neutrophils in children with acute lymphoblastic leukemia.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Plasma levels of 7-hydroxymethotrexate after high-dose methotrexate treatment.

Authors:  G Milano; A Thyss; N Renee; M Schneider; M Namer; J L Boublil; C M Lalanne
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Methotrexate kinetics in myeloid bone marrow cells and peripheral neutrophils.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells.

Authors:  J Jolivet; R L Schilsky; B D Bailey; J C Drake; B A Chabner
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

6.  Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.

Authors:  J Jolivet; B A Chabner
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.